24th Aug 2015 06:44
LONDON (Alliance News) - UK-based drugmaker AstraZeneca PLC and Peregrine Pharmaceuticals Inc Monday said they have entered into a cancer immunotherapy clinical trial collaboration.
The collaboration will evaluate Peregrine's investigational phosphatidylserine signaling pathway inhibitor, bavituximab, in combination with AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab.
The planned Phase I/Ib trial will evaluate the safety and efficacy of bavituximab in combination with durvalumab in multiple solid tumours.
Peregrine and AstraZeneca will collaborate on a non-exclusive basis, to evaluate the combination of bavituximab and durvalumab with chemotherapy as a potential treatment in various solid tumours.
The Phase I part of the trial is expected to establish a recommended dose regimen for the combination and the Phase Ib part of the trial will assess the safety and efficacy of the investigational combination. Under the terms of the agreement, the initial trial will be conducted by Peregrine.
Copyright RTT News/dpa-AFX
Related Shares:
Astrazeneca